Liver Diseases  >>  Imbruvica (ibrutinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imbruvica (ibrutinib) / AbbVie, J&J
NCT01767948: A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Completed
1
30
US
PCI-32765
Janssen Research & Development, LLC
Hepatic Impairment
11/13
11/13

Download Options